C
Concord Biotech Ltd
NSE:CONCORDBIO
Concord Biotech Ltd
NSE:CONCORDBIO
Price:
1 182.2
INR
0.66%
Market Closed
Market Cap:
₹123.7B
Income Statement
Earnings Waterfall
Concord Biotech Ltd
Concord Biotech Ltd
Income Statement
Concord Biotech Ltd
Concord Biotech Ltd
Currency: INR
| Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Interest Expense |
0
|
0
|
25
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
13 103
N/A
|
15 511
+18%
|
10 169
-34%
|
10 379
+2%
|
10 857
+5%
|
10 892
+0%
|
12 001
+10%
|
11 883
-1%
|
11 251
-5%
|
11 587
+3%
|
|
| Gross Profit | |||||||||||
| Cost of Revenue |
(2 735)
|
(3 206)
|
(3 342)
|
(2 371)
|
(2 605)
|
(2 659)
|
(4 177)
|
(4 440)
|
(4 453)
|
(4 870)
|
|
| Gross Profit |
10 369
N/A
|
12 306
+19%
|
6 828
-45%
|
8 008
+17%
|
8 252
+3%
|
8 233
0%
|
7 823
-5%
|
7 442
-5%
|
6 799
-9%
|
6 717
-1%
|
|
| Operating Income | |||||||||||
| Operating Expenses |
(5 826)
|
(6 839)
|
(3 047)
|
(4 139)
|
(4 208)
|
(4 266)
|
(3 274)
|
(3 168)
|
(3 057)
|
(3 019)
|
|
| Selling, General & Administrative |
(1 687)
|
(1 994)
|
(2 432)
|
(1 265)
|
(1 300)
|
(1 339)
|
(2 640)
|
(1 452)
|
(1 560)
|
(1 681)
|
|
| Depreciation & Amortization |
(804)
|
(939)
|
(536)
|
(537)
|
(537)
|
(535)
|
(544)
|
(590)
|
(640)
|
(695)
|
|
| Other Operating Expenses |
(3 335)
|
(3 906)
|
(79)
|
(2 337)
|
(2 371)
|
(2 392)
|
(91)
|
(1 126)
|
(857)
|
(643)
|
|
| Operating Income |
4 543
N/A
|
5 466
+20%
|
3 780
-31%
|
3 870
+2%
|
4 044
+5%
|
3 967
-2%
|
4 549
+15%
|
4 275
-6%
|
3 742
-12%
|
3 698
-1%
|
|
| Pre-Tax Income | |||||||||||
| Interest Income Expense |
(16)
|
9
|
245
|
(33)
|
(21)
|
(29)
|
303
|
(15)
|
38
|
12
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(33)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
|
| Total Other Income |
501
|
583
|
100
|
374
|
393
|
459
|
96
|
478
|
511
|
464
|
|
| Pre-Tax Income |
5 028
N/A
|
6 059
+21%
|
4 126
-32%
|
4 211
+2%
|
4 417
+5%
|
4 397
0%
|
4 946
+12%
|
4 738
-4%
|
4 291
-9%
|
4 141
-3%
|
|
| Net Income | |||||||||||
| Tax Provision |
(1 272)
|
(1 527)
|
(1 045)
|
(1 078)
|
(1 138)
|
(1 135)
|
(1 229)
|
(1 177)
|
(1 057)
|
(1 030)
|
|
| Income from Continuing Operations |
3 756
|
4 532
|
3 081
|
3 132
|
3 279
|
3 263
|
3 716
|
3 561
|
3 234
|
3 111
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
|
| Net Income (Common) |
3 756
N/A
|
4 532
+21%
|
3 081
-32%
|
3 132
+2%
|
3 279
+5%
|
3 263
-1%
|
3 716
+14%
|
3 561
-4%
|
3 234
-9%
|
3 120
-4%
|
|
| EPS (Diluted) |
35.9
N/A
|
43.28
+21%
|
29.45
-32%
|
29.95
+2%
|
50.86
+70%
|
31.19
-39%
|
35.52
+14%
|
34.02
-4%
|
30.82
-9%
|
29.41
-5%
|
|
Switch to:
Switch to:
See Also
Discover More
